Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1972 2
1977 1
1978 2
1979 1
1982 1
1984 1
1986 2
1987 3
1988 1
1990 1
1991 1
1992 2
1994 1
1995 4
1996 1
1997 4
1998 5
1999 4
2000 4
2001 4
2002 5
2003 2
2004 4
2005 5
2006 3
2007 2
2008 6
2009 11
2010 14
2011 2
2012 17
2013 23
2014 31
2015 25
2016 18
2017 33
2018 40
2019 35
2020 50
2021 51
2022 29
2023 38
2024 36
2025 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

442 results

Results by year

Filters applied: Clinical Trial, Humans. Clear all
Page 1
Psilocybin Therapy for Clinicians With Symptoms of Depression From Frontline Care During the COVID-19 Pandemic: A Randomized Clinical Trial.
Back AL, Freeman-Young TK, Morgan L, Sethi T, Baker KK, Myers S, McGregor BA, Harvey K, Tai M, Kollefrath A, Thomas BJ, Sorta D, Kaelen M, Kelmendi B, Gooley TA. Back AL, et al. JAMA Netw Open. 2024 Dec 2;7(12):e2449026. doi: 10.1001/jamanetworkopen.2024.49026. JAMA Netw Open. 2024. PMID: 39636638 Free PMC article. Clinical Trial.
IMPORTANCE: The psychological morbidity experienced by physicians, advanced practice practitioners (APPs), and nurses from working during the COVID-19 pandemic includes burnout, depression, and posttraumatic stress disorder (PTSD). OBJECTIVE: To investigate whether …
IMPORTANCE: The psychological morbidity experienced by physicians, advanced practice practitioners (APPs), and nurses from working during th …
Early augmentation therapy with dextromethorphan in mild to moderate major depressive disorder: A group sequential, response adaptive randomized controlled trial.
Maji S, Mishra A, Mohapatra D, Mishra BR, Jena M, Srinivasan A, Maiti R. Maji S, et al. Psychiatry Res. 2024 Dec;342:116257. doi: 10.1016/j.psychres.2024.116257. Epub 2024 Nov 8. Psychiatry Res. 2024. PMID: 39551007 Clinical Trial.
AIM: Therapeutic latency, lack of response, and adverse drug reactions are major challenges in current treatment approaches for major depressive disorder (MDD). Following the success of ketamine, more clinical research on NMDA antagonists is needed for a safe …
AIM: Therapeutic latency, lack of response, and adverse drug reactions are major challenges in current treatment approaches for major dep …
Novel multi-modal methodology to investigate placebo response in major depressive disorder.
Cusin C, Dillon DG, Belleau E, Normandin MD, Petibon Y, El-Fakri G, Dhaynaut M, Hooker J, Kaptchuk T, McKee M, Hayden E, Meyer A, Jahan A, Origlio J, Ang YS, Brunner D, Kang M, Long Y, Fava M, Pizzagalli DA. Cusin C, et al. J Affect Disord. 2025 Jan 1;368:1-7. doi: 10.1016/j.jad.2024.08.226. Epub 2024 Sep 2. J Affect Disord. 2025. PMID: 39233242 Clinical Trial.
The neurobiological mechanisms underlying the placebo phenomenon in patients with major depressive disorder (MDD) remain largely unknown. The progressive rise in rates of placebo responses within clinical trials over the past two decades may impede the detection of …
The neurobiological mechanisms underlying the placebo phenomenon in patients with major depressive disorder (MDD) remain large …
The effect of intranasal (R,S)-ketamine on symptoms of fatigue in severe major depressive disorder or bipolar depression with and without comorbid alcohol use disorder: Results from a randomized, double-blind, placebo-controlled trial.
Machado-Vieira R, Jones GH, Courtes AC, Ruiz AC, Vecera CM, Henter ID, Lane SD, Zarate CA Jr, Soares JC. Machado-Vieira R, et al. J Affect Disord. 2024 Dec 15;367:281-285. doi: 10.1016/j.jad.2024.08.183. Epub 2024 Aug 28. J Affect Disord. 2024. PMID: 39214377 Clinical Trial.
However, IV ketamine's use is limited by cost and access barriers. To date, no study has evaluated intranasal (IN) ketamine in individuals with fatigue. This study sought to evaluate the anti-fatigue effects of a single 50 mg dose of IN ketamine in ind …
However, IV ketamine's use is limited by cost and access barriers. To date, no study has evaluated intranasal (IN) ketamine …
Efficacy and safety of intravenous ketamine treatment in Japanese patients with treatment-resistant depression: A double-blind, randomized, placebo-controlled trial.
Ohtani Y, Tani H, Nomoto-Takahashi K, Yatomi T, Yonezawa K, Tomiyama S, Nagai N, Kusudo K, Honda S, Moriyama S, Nakajima S, Yamada T, Morisaki H, Iwabuchi Y, Jinzaki M, Yoshimura K, Eiro T, Tsugawa S, Ichijo S, Fujimoto Y, Miyazaki T, Takahashi T, Uchida H. Ohtani Y, et al. Psychiatry Clin Neurosci. 2024 Dec;78(12):765-775. doi: 10.1111/pcn.13734. Epub 2024 Aug 30. Psychiatry Clin Neurosci. 2024. PMID: 39210712 Free PMC article. Clinical Trial.
AIM: Although the antidepressant effect of ketamine on treatment-resistant depression (TRD) has been frequently reported in North American and European countries, evidence is scarce among the Asian population. ...CONCLUSION: Intravenous ketamine outperformed …
AIM: Although the antidepressant effect of ketamine on treatment-resistant depression (TRD) has been frequently reported in No …
A randomised, open-label, pragmatic pilot comparison of oral and intravenous ketamine in treatment-resistant depression.
Kumar PS, Menon V, Andrade C. Kumar PS, et al. Asian J Psychiatr. 2024 Sep;99:104171. doi: 10.1016/j.ajp.2024.104171. Epub 2024 Jul 23. Asian J Psychiatr. 2024. PMID: 39068714 Clinical Trial.
BACKGROUND: For depression, ketamine is more conveniently administered by oral than by intravenous (iv) routes. The relative antidepressant efficacy of oral vs iv ketamine is unknown. OBJECTIVES: To assess the acute efficacy and the persistence of improvement …
BACKGROUND: For depression, ketamine is more conveniently administered by oral than by intravenous (iv) routes. The relative a …
A Phase 1 Assessment of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of (2R,6R)-Hydroxynorketamine in Healthy Volunteers.
Raja SM, Guptill JT, Mack M, Peterson M, Byard S, Twieg R, Jordan L, Rich N, Castledine R, Bourne S, Wilmshurst M, Oxendine S, Avula SGC, Zuleta H, Quigley P, Lawson S, McQuaker SJ, Ahmadkhaniha R, Appelbaum LG, Kowalski K, Barksdale CT, Gufford BT, Awan A, Sancho AR, Moore MC, Berrada K, Cogan GB, DeLaRosa J, Radcliffe J, Pao M, Kennedy M, Lawrence Q, Goldfeder L, Amanfo L, Zanos P, Gilbert JR, Morris PJ, Moaddel R, Gould TD, Zarate CA Jr, Thomas CJ. Raja SM, et al. Clin Pharmacol Ther. 2024 Nov;116(5):1314-1324. doi: 10.1002/cpt.3391. Epub 2024 Jul 25. Clin Pharmacol Ther. 2024. PMID: 39054770 Clinical Trial.
(R,S)-Ketamine (ketamine) is a dissociative anesthetic that also possesses analgesic and antidepressant activity. ...Quantitative electroencephalography (EEG) measurements collected as a PD parameter based on preclinical findings and ketamine's establi …
(R,S)-Ketamine (ketamine) is a dissociative anesthetic that also possesses analgesic and antidepressant activity. ...Quantitat …
Effects of Low-Dose Ketamine Infusion on the Positive and Negative Domains of Hopelessness and Suicidal Thoughts.
Lin WC, Chen MH, Su TP, Li CT, Wu HJ, Tsai SJ, Bai YM, Mao WC, Tu PC. Lin WC, et al. J Clin Psychiatry. 2024 Jul 8;85(3):24m15257. doi: 10.4088/JCP.24m15257. J Clin Psychiatry. 2024. PMID: 39028544 Clinical Trial.
Background: Low-dose ketamine infusion has been demonstrated to exert antisuicidal effects on patients with treatment-resistant depression (TRD) and strong suicidal ideation. ...The diagnosis of depression was based on the Diagnostic and Statistical Manual of …
Background: Low-dose ketamine infusion has been demonstrated to exert antisuicidal effects on patients with treatment-resistant de …
A randomized controlled pilot study of daily intravenous ketamine over three days for treatment-resistant depression.
Pattanaseri K, Lortrakul J, Jaisin K, Srifuengfung M, Sa-Nguanpanich N, Viravan N, Pariwatcharakul P, Makarasara W, Ratta-Apha W. Pattanaseri K, et al. BMC Psychiatry. 2024 Jul 18;24(1):512. doi: 10.1186/s12888-024-05951-5. BMC Psychiatry. 2024. PMID: 39026266 Free PMC article. Clinical Trial.
BACKGROUND: Studies have confirmed the rapid antidepressant action of ketamine in depressive episodes. Nevertheless, a standardized procedure for the delivery of ketamine infusion in individuals suffering from treatment-resistant depression, particular …
BACKGROUND: Studies have confirmed the rapid antidepressant action of ketamine in depressive episodes. Nevertheless, a standar …
Extended-release ketamine tablets for treatment-resistant depression: a randomized placebo-controlled phase 2 trial.
Glue P, Loo C, Fam J, Lane HY, Young AH, Surman P; BEDROC study investigators. Glue P, et al. Nat Med. 2024 Jul;30(7):2004-2009. doi: 10.1038/s41591-024-03063-x. Epub 2024 Jun 24. Nat Med. 2024. PMID: 38914860 Free PMC article. Clinical Trial.
Ketamine has rapid-onset antidepressant activity in patients with treatment-resistant major depression (TRD). The safety and tolerability of racemic ketamine may be improved if given orally, as an extended-release tablet (R-107), compared with other routes of …
Ketamine has rapid-onset antidepressant activity in patients with treatment-resistant major depression (TRD). The safety and t …
442 results